Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 13/20 | 0.78 |
| ▸ | ERBB2 | P04626 | 13/20 | 0.78 |
| ▸ | KDR | P35968 | 6/20 | 0.71 |
| ▸ | LCK | P06239 | 5/20 | 0.71 |
| ▸ | CSF1R | P07333 | 5/20 | 0.71 |
| ▸ | RET | P07949 | 5/20 | 0.71 |
| ▸ | MAP4K2 | Q12851 | 5/20 | 0.71 |
| ▸ | STK3 | Q13188 | 5/20 | 0.71 |
| ▸ | MAP4K5 | Q9Y4K4 | 5/20 | 0.71 |
| ▸ | MAP4K4 | O95819 | 4/20 | 0.71 |
| ▸ | TAOK1 | Q7L7X3 | 4/20 | 0.71 |
| ▸ | FLT1 | P17948 | 4/20 | 0.71 |
| ▸ | LRRK2 | Q5S007 | 2/20 | 0.71 |
| ▸ | IGF1R | P08069 | 13/20 | 0.68 |
| ▸ | PRKD3 | O94806 | 3/20 | 0.66 |
| ▸ | FYN | P06241 | 3/20 | 0.66 |
| ▸ | AURKB | Q96GD4 | 3/20 | 0.66 |
| ▸ | MET | P08581 | 2/20 | 0.66 |
| ▸ | ROS1 | P08922 | 2/20 | 0.66 |
| ▸ | ROCK1 | Q13464 | 1/20 | 0.66 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1364263 | 0.90 | IGF1R (0.76) | EGFRERBB2KDRLCKCSF1R | |
| SCHEMBL1363158 | 0.88 | EGFR (0.88) | EGFRERBB2KDRLCKCSF1R | |
| SCHEMBL1361289 | 0.88 | EGFR (1.00) | EGFRERBB2KDRLCKCSF1R | |
| SCHEMBL1362161 | 0.87 | EGFR (0.88) | EGFRERBB2KDRLCKCSF1R | |
| SCHEMBL1362277 | 0.87 | EGFR (0.88) | EGFRERBB2KDRLCKCSF1R | |
| SCHEMBL1364275 | 0.87 | EGFR (0.91) | EGFRERBB2KDRLCKCSF1R | |
| SCHEMBL1361437 | 0.85 | EGFR (0.91) | EGFRERBB2KDRLCKCSF1R | |
| SCHEMBL1363144 | 0.84 | EGFR (0.85) | EGFRERBB2KDRLCKCSF1R | |
| SCHEMBL1361597 | 0.84 | EGFR (0.82) | EGFRERBB2KDRLCKCSF1R | |
| SCHEMBL1361757 | 0.84 | EGFR (0.79) | EGFRERBB2KDRLCKCSF1R |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8067409-B2 | Protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | claimed |
| US-8067409-B2 | Protein kinase inhibitors | ABBOTT LABORATORIES (US) | 2011-11-29 | — | — | US | disclosed |
| EP-2222682-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | Abbott Laboratories (US) | 2010-09-01 | — | — | EP | disclosed |
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-10-08 | — | — | US | disclosed |
| WO-2009070516-A1 | IMIDAZO-THIAZOLE DERIVATIVES AS PROTEIN KINASE INHIBITORS | ABBOTT LABORATORIES (US) | 2009-06-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090253723-A1 | PROTEIN KINASE INHIBITORS | PACSIN2, MAP3K20, PHKG1 | EGFR 591/4885ERBB2 270/4885KDR 1617/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.